These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 19775628

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Management and interpretation of novel toxicities of molecular targeted therapies: renal toxicities.
    Carles J, Morales R, Perez JM, Suárez C, Rodón J, Valverde C.
    Eur J Cancer; 2009 Sep; 45 Suppl 1():309-17. PubMed ID: 19775627
    [No Abstract] [Full Text] [Related]

  • 3. Targeted therapies: a new generation of cancer treatments.
    Gerber DE.
    Am Fam Physician; 2008 Feb 01; 77(3):311-9. PubMed ID: 18297955
    [Abstract] [Full Text] [Related]

  • 4. Anti-EGFR therapy update: clinical experience and adverse event insights.
    Harari PM.
    Oncology (Williston Park); 2006 Apr 01; 20(5 Suppl 2):3-4. PubMed ID: 16736977
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Cutaneous reactions related to systemic immunomodulators and targeted therapeutics.
    Hammond-Thelin LA.
    Dermatol Clin; 2008 Jan 01; 26(1):121-59, ix. PubMed ID: 18023775
    [Abstract] [Full Text] [Related]

  • 7. Metastatic colorectal cancer.
    Saletti P, Cavalli F.
    Cancer Treat Rev; 2006 Nov 01; 32(7):557-71. PubMed ID: 16935430
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Pharmacogenetics of EGFR and VEGF inhibition.
    Pander J, Gelderblom H, Guchelaar HJ.
    Drug Discov Today; 2007 Dec 01; 12(23-24):1054-60. PubMed ID: 18061885
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Mechanisms of cutaneous toxicities to EGFR inhibitors.
    Lacouture ME.
    Nat Rev Cancer; 2006 Oct 01; 6(10):803-12. PubMed ID: 16990857
    [Abstract] [Full Text] [Related]

  • 14. Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events.
    Lenz HJ.
    Oncology (Williston Park); 2006 Apr 01; 20(5 Suppl 2):5-13. PubMed ID: 16736978
    [Abstract] [Full Text] [Related]

  • 15. Sequencing therapies: the role of targeted agents in metastatic colorectal cancer.
    Oestreicher P.
    ONS Connect; 2007 Apr 01; 22(8 Suppl):37-8. PubMed ID: 17824557
    [No Abstract] [Full Text] [Related]

  • 16. Management of hypomagnesemia in cancer patients receiving chemotherapy.
    Saif MW.
    J Support Oncol; 2008 Apr 01; 6(5):243-8. PubMed ID: 18551863
    [No Abstract] [Full Text] [Related]

  • 17. Keys to unlock cancer: targeted therapy.
    Viele CS.
    Oncol Nurs Forum; 2005 Sep 01; 32(5):935-40. PubMed ID: 16136192
    [No Abstract] [Full Text] [Related]

  • 18. Angiotensin-converting enzyme inhibitors for bevacizumab-induced hypertension.
    Dincer M, Altundag K.
    Ann Pharmacother; 2006 Dec 01; 40(12):2278-9. PubMed ID: 17105834
    [No Abstract] [Full Text] [Related]

  • 19. The changing paradigm of colorectal cancer therapy: the impact of vascular endothelial growth factor and epidermal growth factor and epidermal growth factor receptor inhibition. Introduction.
    Chase JL.
    Pharmacotherapy; 2008 Nov 01; 28(11 Pt 2):17S. PubMed ID: 18980547
    [No Abstract] [Full Text] [Related]

  • 20. Targeted agents and esophageal cancer--the next step?
    Aklilu M, Ilson DH.
    Semin Radiat Oncol; 2007 Jan 01; 17(1):62-9. PubMed ID: 17185199
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.